López M., Escobar A., Alfaro J., Fodor M., Larrondo M., Ferreda C., Salazar- Onfray F. Avances en inmunoterapia celular contra el melanoma maligno. Rev Med Chile, 2004; 132: 1115-1126.
López M., Aguilera R., Pérez C., Mendoza-Naranjo A., Pereda C., Ramírez M., Ferrada C., Agullón J., Salazar-Onfray F. The role of regulatory T lymphocytes in the induced inmune response mediated by biological vaccines. Inmunobiology 211 (2006) 127-136.
Tuettenberg A., Schimtt E., Knop J., Jonuleit H. Dendritic Cell-Based Inmunotherapy of Malignant Melanoma: Succes and Limitations. JDDG: Journal der Deutschen Dermatologischen Gesellschaft Volume 5, Issue 3, pages 190–196, March 2007
Nestlé F., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R.,m Burg G., Schadendorf D. Vaccination of melanoma patients with peptide or tumour lysate-pulsed dendritic cells. Nature Medicine v. 4 n.3 march 1998.
P Kyte JA. Mu L., Aamdal S., Kvalheim G., Dueland S., Hauser M., Gullestad HP., Ryder T., Lislerud K., Hammerstad H. Gaudernack G. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-m RNA. Cancer Gene Therapy (2006) 13, 905-918
Kyte J., Kvalheim G., Lislerud K., Straten p., Dueland S., Aamdal S., Gaudernack G. T cell responses in melanoma patients after vaccination with tumor- m RNA transfected dendritic cells. Cancer Inmunol Inmunotherapy (2007) 56:659-675.
O’Rourke MG, Johnson M, Lanagan C, et al:Durable complete clinical responses in a phase I/IItrial using an autologous melanoma cell/dendritic ell vaccine. Cancer Immunol Immunotherapy 52:387-395, 2003
Trefzer U, Herberth G, Wohlan K, et al: Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: Immunological effects and clinical results. Vaccine 23:2367- 2373, 2005
López, M., Pereda C., Segal. G et al. Prolonged Survival of dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor _-Expressing T Cells. Journal of Clinical Oncology v.27 n.6 2009.
El sistema immune, herramnienta estratégica en la batalla contra el cáncer. Salazar-Onfray F. Rev. Chil. Pediatría v. 71 n.4 2000.
Gutiérrez C, Alarcón E, Valle R, Calderón G. Epidemiología del melanoma maligno en el Instituto Nacional de Enfermedades Neoplásicas, Perú, 2000-2004. Folia dermatol. Peru 2007; 18 (1): 23-27
Iribarren O, Sepúlveda M, Hidalgo J, Madariaga J. Estudio epidemiológico de melanoma maligno en la IV Región de Chile. Cuad. Cir. 2005; 19: 33-38
Zemelman V, Molina P, Valenzuela C, Honeyman J. Análisis de la densidad y distribución anatómica de nevos melanocíticos adquiridos, en adolescentes del estrato socioeconómico bajo de Santiago de Chile. Rev Méd Chile 2008; 136: 747-752.